Table 2.
Clinical success rates by study population at the test-of-cure visit
| Tigecycline CE population N = 209 (%) | Comparator CE population N = 196 (%) | Difference (Tigecycline vs Comparator)†(95% CI) | |
|---|---|---|---|
|
Clinical diagnoses* | |||
| Deep soft tissue infections |
114/150 (76.0) |
103/132 (78.0) |
-2.0 (-12.6, 8.5) |
| Major abscess |
30/36 (83.3) |
34/43 (79.1) |
4.3 (-15.5, 24.0) |
| Infected ulcers |
17/22 (77.3) |
15/20 (75.0) |
2.3 (-28.3, 32.9) |
|
Other populations | |||
| Diabetes mellitus |
46/60 (76.7) |
46/66 (69.7) |
7.0 (-10.0, 24.0) |
| Peripheral vascular disease |
20/27 (74.1) |
16/20 (80.0) |
-5.9 (-34.4, 22.5) |
| Prior antibiotic failure | 27/35 (77.1) | 26/34 (76.5) | 0.7 (-22.1, 23.5) |
*Includes 2 CE patients with burns: 1 tigecycline cure and 1 comparator failure; †Calculated using asymptomatic method corrected for continuity. CE, clinically evaluable; CI, confidence interval.